NO20076002L - Anvendelse av agomelatin for a oppna medikamenter tiltenkt for behandlingen av periventrikulaer levkomalasi - Google Patents

Anvendelse av agomelatin for a oppna medikamenter tiltenkt for behandlingen av periventrikulaer levkomalasi

Info

Publication number
NO20076002L
NO20076002L NO20076002A NO20076002A NO20076002L NO 20076002 L NO20076002 L NO 20076002L NO 20076002 A NO20076002 A NO 20076002A NO 20076002 A NO20076002 A NO 20076002A NO 20076002 L NO20076002 L NO 20076002L
Authority
NO
Norway
Prior art keywords
agomelatine
periventricular
treatment
lymphoma
medications intended
Prior art date
Application number
NO20076002A
Other languages
English (en)
Other versions
NO338598B1 (no
Inventor
Michael Spedding
Elisabeth Mocaer
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38229589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20076002(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of NO20076002L publication Critical patent/NO20076002L/no
Publication of NO338598B1 publication Critical patent/NO338598B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse vedrører anvendelsen av agomelatin, eller N-[2-(7-metoksy-1-naftyl)etyl]acetamid, for å oppnå medikamenter tiltenkt for behandlingen av periventrikulær levkomalasi. - 1 -
NO20076002A 2006-11-24 2007-11-23 Anvendelse av agomelatin for å oppnå medikamenter tiltenkt for behandlingen av periventrikulær levkomalasi NO338598B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0610294A FR2908994B1 (fr) 2006-11-24 2006-11-24 Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement de la leucomalacie periventriculaire

Publications (2)

Publication Number Publication Date
NO20076002L true NO20076002L (no) 2008-05-26
NO338598B1 NO338598B1 (no) 2016-09-12

Family

ID=38229589

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076002A NO338598B1 (no) 2006-11-24 2007-11-23 Anvendelse av agomelatin for å oppnå medikamenter tiltenkt for behandlingen av periventrikulær levkomalasi

Country Status (37)

Country Link
US (1) US20080125493A1 (no)
EP (1) EP1927351B1 (no)
JP (1) JP4870062B2 (no)
KR (1) KR100976000B1 (no)
CN (1) CN101185644B (no)
AR (1) AR063895A1 (no)
AT (1) ATE483458T1 (no)
AU (1) AU2007234600B2 (no)
BR (1) BRPI0704179A (no)
CA (1) CA2610637C (no)
CL (1) CL2007003395A1 (no)
CY (1) CY1110875T1 (no)
DE (1) DE602007009627D1 (no)
DK (1) DK1927351T3 (no)
EA (1) EA014067B1 (no)
ES (1) ES2353128T3 (no)
FR (1) FR2908994B1 (no)
GE (1) GEP20094747B (no)
HR (1) HRP20100680T1 (no)
JO (1) JO2631B1 (no)
MA (1) MA29522B1 (no)
ME (1) ME01866B (no)
MX (1) MX2007014004A (no)
MY (1) MY145925A (no)
NO (1) NO338598B1 (no)
NZ (1) NZ563683A (no)
PE (1) PE20081158A1 (no)
PL (1) PL1927351T3 (no)
PT (1) PT1927351E (no)
RS (1) RS51494B (no)
SG (1) SG143202A1 (no)
SI (1) SI1927351T1 (no)
TW (1) TW200829236A (no)
UA (1) UA94043C2 (no)
UY (1) UY30703A1 (no)
WO (1) WO2008071869A2 (no)
ZA (1) ZA200710102B (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2810656T3 (pl) 2013-06-06 2018-01-31 Zentiva Ks Preparaty agomelatyny zawierające agomelatynę w postaci kokryształów
EP2810647A1 (en) * 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2003011271A2 (en) * 2001-08-03 2003-02-13 Children's Medical Center Corporation Methods and compositions for modulating brain damage
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
US7358395B2 (en) * 2005-08-03 2008-04-15 Les Laboratories Servier Crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it

Also Published As

Publication number Publication date
CN101185644B (zh) 2011-08-10
EA200702317A1 (ru) 2008-06-30
PL1927351T3 (pl) 2011-01-31
PE20081158A1 (es) 2008-10-04
CA2610637A1 (fr) 2008-05-24
ZA200710102B (en) 2008-11-26
CA2610637C (fr) 2011-04-19
ME01866B (me) 2011-04-30
PT1927351E (pt) 2010-10-27
JP2008133279A (ja) 2008-06-12
CY1110875T1 (el) 2015-06-10
ES2353128T3 (es) 2011-02-25
WO2008071869A3 (fr) 2008-08-14
KR20080047298A (ko) 2008-05-28
SG143202A1 (en) 2008-06-27
GEP20094747B (en) 2009-07-27
US20080125493A1 (en) 2008-05-29
ATE483458T1 (de) 2010-10-15
NZ563683A (en) 2009-04-30
MA29522B1 (fr) 2008-06-02
AU2007234600B2 (en) 2012-05-17
UA94043C2 (ru) 2011-04-11
AU2007234600A1 (en) 2008-06-12
UY30703A1 (es) 2008-01-02
CL2007003395A1 (es) 2008-09-12
CN101185644A (zh) 2008-05-28
KR100976000B1 (ko) 2010-08-17
BRPI0704179A (pt) 2008-07-08
TW200829236A (en) 2008-07-16
AR063895A1 (es) 2009-02-25
DK1927351T3 (da) 2011-01-10
RS51494B (sr) 2011-04-30
FR2908994B1 (fr) 2009-04-03
EA014067B1 (ru) 2010-08-30
DE602007009627D1 (de) 2010-11-18
EP1927351B1 (fr) 2010-10-06
FR2908994A1 (fr) 2008-05-30
JO2631B1 (en) 2012-06-17
WO2008071869A2 (fr) 2008-06-19
MY145925A (en) 2012-05-15
NO338598B1 (no) 2016-09-12
SI1927351T1 (sl) 2010-12-31
JP4870062B2 (ja) 2012-02-08
HK1118216A1 (en) 2009-02-06
EP1927351A1 (fr) 2008-06-04
AU2007234600A8 (en) 2010-12-02
MX2007014004A (es) 2009-02-16
HRP20100680T1 (hr) 2011-01-31

Similar Documents

Publication Publication Date Title
NO20071774L (no) Anvendelse av agomelatin for a oppna medikamenter tiltenkt for behandlingen av generalisert angstlidelse
CL2008001465A1 (es) Compuestos derivados de [2,1,3]benzoxadiazol-5-carboxamidas, moduladores de los receptores ampa; composiciones farmacéuticas; y su uso en el tratamiento de afecciones hipoglutamatérgicas, trastornos cognitivos, enfermedad de parkinson, adhd, síndrome de rett, depresión respiratoria, síndrome x frágil y enfermedad de alzheimer.
NO20075989L (no) Anvendelse av agomelatin for a oppna medikamenter tiltenkt for behandlingen av Smith-Magenis syndrom
NO20064050L (no) Anvendelse av agomelatin for a oppna medikamenter tiltenkt for behandlingen av sovnforstyrrelser i den deprimerte pasient
TNSN07364A1 (en) Use of agomelatine for obtaining medicaments used for treating bipolar disorders
EA200702317A1 (ru) Применение агомелатина для получения лекарственных средств, предназначенных для лечения перивентрикулярной лейкомаляции
NO20064048L (no) Ny assosiasjon mellom agomelatin og en nordadrenalin-reopptaksinhibitor, og farmasoytiske sammensetninger inneholdende den
EA201201286A1 (ru) Новое биологически активное соединение n-[3-(нитрофениламино)индол-2-илметилен]аминогуанидина гидрохлорид с противовоспалительной активностью
EA200601450A1 (ru) Новая комбинация агомелатина и тиморегулирующего средства и фармацевтические композиции, которые её содержат
CU20070232A7 (es) Utilización de la agomelatina para la obtención de medicamentos destinados al tratamiento de los trastornos bipolares
CU20070070A7 (es) Composición farmacéutica de agomelatina
TH138902A (th) ผลึกร่วมแบบใหม่ของอะโกเมลาทีน กระบวนการในการเตรียมสารดังกล่าวและองค์ประกอบทางเภสัชกรรมที่ประกอบด้วยสารดังกล่าว

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees